US Edition
Myriad Genetics, Inc. (MYGN) Stock Analysis: Is A 25% Upside Potential Within Reach?
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Myriad Genetics, Inc. (MYGN) Stock Analysis: Is A 25% Upside Potential Within Reach?
Myriad Genetics, Inc. (NASDAQ: MYGN) presents a curious case for investors in the healthcare sector, particularly within the diagnostics and research industry. Headquartered in Salt Lake City, Utah, this molecular diagnostic leader specializes in precision medicine, offering a suite of tests that include the MyRisk Hereditary Cancer test and the BRACAnalysis CDx Germline Companion Diagnostic test among others. While the company’s innovative port…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
